An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1

Date Added
December 30th, 2024
PRO Number
Pro00141056
Researcher
Eric Meissner

List of Studies


Keywords
HIV / AIDS
Summary

The main objective of this study is to test a once-weekly HIV medication regimen in persons who have not taken HIV treatment before. The goal is to see if taking a once a week pill combination (GS-1720 and GS-4182) works as well as taking a daily pill Biktarvy® (B/F/TAF). Participants will either take the weekly pill or continue with Biktarvy® for about 48 weeks or longer. The study will look at how well each option controls HIV levels.

Institution
MUSC
Recruitment Contact
Jamila Williams
(843) 792-1088
keithja@musc.edu

Impacts of drug abuse-mediated inflammatory perturbations on affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from ART in HIV

Date Added
November 6th, 2024
PRO Number
Pro00140552
Researcher
Wei Jiang

List of Studies


Keywords
Drug Studies, HIV / AIDS
Summary

This study is to understand HIV-infected cocaine users have poor immunity after anti-HIV treatment, but HIV-infected cannabis users are likely different. Cocaine use always is associated high inflammation and cannabis use is associated with low inflammation. We study how inflammation cannot be controlled in cocaine users; our goal is to develop new therapies to help cocaine users to have a better health and immunity.

Institution
MUSC
Recruitment Contact
Wei Jiang
8438762457
jianw@musc.edu

Perspectives on Treatment with CAB+RPV LA Injectable Therapy from People Living with HIV (PWH) in the US with Prior Adherence Challenges to Oral ART

Date Added
April 12th, 2024
PRO Number
Pro00132072
Researcher
Stephanie Kirk

List of Studies


Keywords
HIV / AIDS
Summary

This is a cross-sectional survey in persons with HIV infection to evaluate experiences of historical oral therapy use and how their perceptions on treatment may have changed with the availability of injectable long-acting therapy. In
addition to surveys, a corresponding retrospective medical chart review will be conducted for each participant.

Institution
MUSC
Recruitment Contact
Alicia Hartley
843-792-4100
hartleal@musc.edu

Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine Users

Date Added
October 26th, 2023
PRO Number
Pro00131297
Researcher
Wei Jiang

List of Studies


Keywords
Drug Studies, HIV / AIDS
Summary

HIV infected cocaine users have uncontrolled viral levels and impaired immunity to control infection compared to HIV infected non-drug users. We ask the questions why cocaine use makes HIV infected cocaine users more sick than other patients. The goal is to improve immunity to control HIV infection in cocaine users. Both uninfected cocaine users and HIV-infected cocaine users are especially needed in this study.

Institution
MUSC
Recruitment Contact
Alicia Hartley
843-792-4100 (Alicia); 843-876-2457 (Wei)
hartleal@musc.edu (Alicia); jianw@musc.edu (Wei)

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

Date Added
March 16th, 2023
PRO Number
Pro00125361
Researcher
Eric Meissner

List of Studies


Keywords
HIV / AIDS
Summary

The primary objective of this study is to determine how bictegravir (BIC) plus lenacapvir (LEN) in two different doses affects an HIV-1 infection in the body compared with current standard treatment regimens. Other objectives are to determine which of these treatments are the most effective for treating HIV-1 infection, the safety and tolerability of these two doses for people with HIV, as well as how long it stays in the body using physical exams, laboratory tests, ECG, blood analysis, and any symptoms or problems experienced during the study.

Institution
MUSC
Recruitment Contact
Marion Campbell
843-792-8894
cammario@musc.edu